Dr. Andrew Zelenetz on the Impact of Rituximab in Lymphoma 

Andrew D. Zelenetz, MD, PhD, Vice Chair, Medical Informatics, Department of Medicine; Chief, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, explains the impact that rituximab (Rituxan) has made in the treatment of patients with non-Hodgkin and B-cell lymphomas.
For more on lymphoma and other hematologic malignancies, visit www.onclive.com/specialty/hema...